Rheumatoid arthritis and erectile dysfunction can occur together for reasons that extend beyond joint pain. Rheumatoid arthritis (RA) is a systemic autoimmune disease: inflammation affects the synovial lining of joints, but its effects can also involve blood vessels, energy, mood, sleep, and cardiovascular risk. Each of those domains can influence sexual function. Research suggests an association, although estimates vary substantially and do not prove that RA directly causes erectile dysfunction (ED) in every affected man.
Rheumatoid Arthritis and Erectile Dysfunction in Clinical Studies
Sexual symptoms are not routinely discussed in rheumatology visits, so prevalence is difficult to measure. Studies use different definitions, questionnaires, age groups, and control populations. Some assess erectile function specifically, while others combine desire, arousal, orgasm, pain, and satisfaction under the broader category of sexual dysfunction.
A 2018 systematic review and meta-analysis by Zhao and colleagues combined seven observational studies with 44,745 participants. In the male subgroup, RA was associated with nearly twice the relative risk of sexual dysfunction compared with controls. However, the authors rated the overall certainty of evidence as low because the studies were observational and heterogeneous.[1] The result identifies a signal, not a precise individual risk.
A broader 2020 systematic review examined 55 studies of inflammatory arthritis. Across studies using the International Index of Erectile Function, average scores in male inflammatory-arthritis groups fell within ranges consistent with ED. The review also highlighted substantial variation in methods and limited evidence about which interventions improve sexual outcomes.[2]
More recent population data complicate the picture. A 2024 analysis of U.S. National Health and Nutrition Examination Survey data found that arthritis overall was associated with ED after full adjustment. Yet when arthritis was separated by subtype, the association remained statistically significant for osteoarthritis but not for RA.[3] Similarly, a population-based cohort study from Wilton and colleagues found no statistically significant increase in newly diagnosed ED among men with RA compared with age-matched controls.[4]
These findings are not necessarily contradictory. Survey studies may capture symptoms that never reach a medical record, while cohort studies based on diagnoses can miss men who do not seek care. Disease severity, treatment era, age, cardiovascular health, and the definition of ED also differ. The defensible conclusion is that sexual dysfunction is common enough in RA to ask about, but RA alone does not determine whether a man will develop ED.
How Systemic Inflammation May Affect Erections
An erection begins when sexual stimulation activates nitric oxide signaling. This relaxes smooth muscle in penile arteries and erectile tissue, increasing blood inflow. Expanded erectile tissue then compresses draining veins, helping maintain rigidity. Healthy endothelium—the cellular lining of blood vessels—is central to this response.
RA produces chronic elevations in inflammatory mediators such as tumor necrosis factor alpha, interleukin-6, and C-reactive protein, especially when disease activity is poorly controlled. Persistent inflammation can reduce endothelial nitric oxide availability, increase oxidative stress, and promote arterial stiffness. These mechanisms are biologically capable of weakening the vascular response required for erection. They also contribute to the excess cardiovascular burden associated with RA.
Traditional vascular risks often accumulate alongside inflammation. Smoking is a recognized RA risk factor and a direct risk factor for ED. Hypertension, insulin resistance, abnormal lipids, physical inactivity, and central obesity can further impair endothelial function. A man with RA and new ED therefore needs assessment for ordinary cardiometabolic causes, not an assumption that joint disease explains everything.
The vascular link should also be interpreted carefully. In the Wilton cohort, ED was not more common among men with RA and did not predict a clear increase in overall cardiovascular events within that RA population.[4] The study did observe an imprecise trend toward peripheral arterial disease, but the confidence interval included no effect. ED remains a reason to review cardiovascular health; it is not a diagnosis of hidden heart disease.
Pain, Fatigue, Mobility, and Mental Health
RA can affect sexual function without directly altering penile blood flow. Hand, hip, knee, spine, or shoulder pain may make particular positions uncomfortable. Morning stiffness can limit movement, and fatigue may reduce both opportunity and desire. In a clinical study of 231 people with RA, 53.8% of the 91 men reported sexual dysfunction. Erectile symptoms correlated with pain, fatigue, disease activity, tender-joint count, age, and cardiovascular disease.[5]
That study was cross-sectional, so it cannot establish which factor came first. Still, it illustrates why a purely vascular explanation is incomplete. Pain anticipates pain: a man may avoid sexual activity or lose arousal when he expects a joint to hurt. Reduced activity can then affect conditioning, mood, relationship communication, and confidence.
Depression and anxiety are more common in chronic inflammatory disease and independently associated with ED. Performance anxiety can turn an occasional difficulty into a recurring pattern by increasing sympathetic nervous-system activity, which opposes the relaxation needed for an erection. Body-image changes, fear of rejection, and concern about burdening a partner can also reduce intimacy.
Practical adjustments may help. Sexual activity can be planned for the time of day when stiffness is lowest. Pillows or supportive surfaces can reduce load on painful joints, and positions can be modified to require less grip strength or hip movement. Clinician-approved pain management before activity may be useful. Couples or sex therapy can address avoidance and communication without implying that symptoms are “only psychological.”
Medications, Hormones, and Disease Control
Men sometimes attribute ED to an RA medication, but stopping disease-modifying therapy without guidance can increase inflammation and make pain, fatigue, and vascular risk worse. The medication review should be specific rather than categorical.
Glucocorticoids can contribute to weight gain, glucose intolerance, hypertension, mood changes, and suppression of the hypothalamic-pituitary-gonadal axis when exposure is substantial or prolonged. Opioids used for chronic pain can suppress testosterone and libido. Some antidepressants and antihypertensive drugs may impair sexual function. Nonsteroidal anti-inflammatory drugs and conventional or biologic disease-modifying antirheumatic drugs have different risk profiles; an association in an individual patient requires attention to timing, dose, competing causes, and what happens when therapy changes under supervision.
Testosterone should not be assumed to be low simply because desire or erections have changed. Testing is most informative when symptoms are compatible and blood is drawn in the morning, usually with confirmation of an abnormal result. Thyroid disease, elevated prolactin, anemia, sleep apnea, and diabetes may produce overlapping fatigue or sexual symptoms and can be investigated when the history supports them.
Good RA control may support sexual function indirectly by reducing pain, fatigue, disability, and inflammatory burden. However, no disease-modifying antirheumatic drug is established as an ED treatment. Improvement in sexual symptoms after better disease control is clinically meaningful, but it does not show that a specific immune pathway was the sole cause.
Evaluation and Treatment Should Address Both Conditions
A useful evaluation separates erection quality from desire, orgasm, ejaculation, pain, and relationship concerns. The onset and pattern matter: gradual loss of rigidity with fewer morning erections suggests a different mix of causes than situational difficulty with preserved spontaneous erections. Clinicians may use a validated tool such as the five-item International Index of Erectile Function to establish severity and track response.
Basic assessment commonly includes blood pressure, cardiovascular and neurologic history, medication and substance review, and laboratory testing for glucose and lipids. Morning testosterone and other tests are selected according to symptoms. RA disease activity, pain, fatigue, mobility, and mental health should be reviewed in parallel. Penile pain, new curvature, neurologic deficits, or symptoms following pelvic surgery warrant focused evaluation.
Treatment is individualized. Smoking cessation, regular aerobic activity within joint limitations, resistance exercise, sleep treatment, and management of blood pressure or diabetes may support endothelial health. Rheumatology care should aim for appropriate disease control. Physical or occupational therapy can help men move comfortably and conserve energy during daily and sexual activity.
Phosphodiesterase type 5 inhibitors—including tadalafil, sildenafil, and vardenafil—are standard first-line options for many men with ED. They enhance nitric oxide–cyclic GMP signaling but require sexual stimulation and do not directly treat pain, low desire, or relationship distress. They must not be used with nitrate medication, and men with unstable cardiovascular symptoms need medical clearance. Men should not combine ED medications or change RA treatment without clinician oversight.
Conclusion
Rheumatoid arthritis and ED overlap through several plausible pathways: systemic inflammation and vascular dysfunction, cardiovascular risk factors, pain, fatigue, restricted mobility, mood, hormones, and medication effects. Some studies show substantially more sexual dysfunction in men with RA, while newer adjusted analyses find no independent increase in ED. That uncertainty is a reason for careful assessment, not dismissal. Treating joint disease, vascular risk, physical limitations, and sexual symptoms as connected but distinct problems gives clinicians the best chance of identifying reversible contributors.
If you're exploring clinically-formulated options, OnyxMD's Red Pill is available through physician-supervised treatment plans starting with a free online assessment at questionnaire.getonyxmd.com. You can also review additional evidence-based men's health topics in the OnyxMD blog.
These statements have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice.
References
Zhao S, Li E, Wang J, Luo L, Luo J, Zhao Z. Rheumatoid arthritis and risk of sexual dysfunction: A systematic review and metaanalysis. The Journal of Rheumatology. 2018;45(10):1375-1382. doi:10.3899/jrheum.170956
Restoux LJ, Dasariraju SR, Ackerman IN, Van Doornum S, Romero L, Briggs AM. Systematic review of the impact of inflammatory arthritis on intimate relationships and sexual function. Arthritis Care & Research. 2020;72(1):41-62. doi:10.1002/acr.23857
Liu C, Lei Q, Li J, Liu W. Arthritis increases the risk of erectile dysfunction: Results from the NHANES 2001-2004. Frontiers in Endocrinology. 2024;15:1390691. doi:10.3389/fendo.2024.1390691
Wilton KM, Achenbach SJ, Davis JM III, Myasoedova E, Matteson EL, Crowson CS. Erectile dysfunction and cardiovascular risk in men with rheumatoid arthritis: A population-based cohort study. The Journal of Rheumatology. 2021;48(11):1641-1647. doi:10.3899/jrheum.201226
El Miedany Y, El Gaafary M, El Aroussy N, Youssef S, Ahmed I. Sexual dysfunction in rheumatoid arthritis patients: Arthritis and beyond. Clinical Rheumatology. 2012;31(4):601-606. doi:10.1007/s10067-011-1891-2
Medical Disclaimer: The information provided on this website is for educational and informational purposes only and is not intended as medical advice. OnyxMD services should not be used to diagnose, treat, cure, or prevent any disease or medical condition. Always consult with a qualified healthcare provider before beginning any supplement regimen or health program.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Individual Results: Results may vary. The experiences and testimonials presented on this website are individual results that may not be typical. Your experience may be different.
Telehealth Services: OnyxMD provides telehealth services in 47 states (excluding AK, MS, NJ) through licensed healthcare providers via our partner Beluga Health, P.A. Services are subject to clinical evaluation and may not be appropriate for all individuals. Prescriptions fulfilled by Strive Pharmacy LLC (License #99-9817) and EPIQ SCRIPTS LLC.